NCT00766116 - Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 26, 2014

Study Completion Date

September 26, 2014

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

5-Azacitidine

Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.

DRUG

Gemtuzumab ozogamicin

Mylotarg given 2 times over 2 weeks

Trial Locations (3)

30342

Northside Hospital/BMTGA, Atlanta

92093

UCSD Moores Cancer Center, La Jolla

94305

Stanford University, Stanford